

Anti-Infective Drugs Advisory Committee Meeting

November 18, 2008

Non-Inferiority Margin Justification for complicated Skin and Skin Structure Infections (cSSSI)
Holiday Inn/College, Maryland

Tentative Meeting Roster

ACTING CHAIR (Temporary Member)(Voting)

L. Barth Reller, M.D.

Professor of Medicine and Pathology
Duke University Medical Center
Durham, NC

Designated Federal Officer

Janie Kim, Pharm.D.

5630 Fishers Lane, HFD-21
Rockville, MD
Janie.kim@fda.hhs.gov

ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Dean Follmann, Ph.D.

Chief, Biostatistics Research Branch
Office of Clinical Research
National Institute of Allergy and
Infectious Diseases (NIAID)
Bethesda, MD

Carol Kauffman, M.D.

Chief, Infectious Diseases
Veterans Administration Healthcare System
Ann Arbor, MI

Kathleen Gutierrez, M.D.

Assistant Professor
Department of Pediatrics
Stanford University School of Medicine
Stanford, CA

Bernhard Wiedermann, M.D.

Attending, Infectious Disease
Children's National Medical Center
Washington, D.C.

INDUSTRY REPRESENTATIVE (Non-Voting)

John H. Rex, M.D., F.A.C.P.

Infection Clinical Vice President
AstraZeneca; Alderley House
United Kingdom

Meeting of the Anti-Infective Drugs Advisory Committee

November 18, 2008

Non-Inferiority Margin Justification for complicated Skin and Skin Structure Infections (cSSSI)
Holiday Inn/College, Maryland

Tentative Meeting Roster (continued)

TEMPORARY MEMBERS (Voting)

W. Kemper Alston, M.D.

Associate Professor of Medicine
University of Vermont
Burlington, VT

John Bennett, M.D.

Section Chief, Clinical Mycology
National Institute of Allergy
and Infectious Diseases
Bethesda, MD

Alan Cross, M.D.

Professor of Medicine
University of Maryland School of Medicine
Center for Vaccine Development
Baltimore, MD

Thomas Fleming, Ph.D.

Professor of Biostatistics
University of Washington
Seattle, WA

Matthew Goetz, M.D.

Director
VA Greater Los Angeles Healthcare System
Los Angeles, CA

Joan F. Hilton, Sc.D., M.P.H.

Professor, Division of Biostatistics
University of California, San Francisco
San Francisco, CA

Peter Katona, M.D., FACP

Associate Professor
The David Geffen School of Medicine
University of California Los Angeles (UCLA)
Los Angeles, CA

Timothy Lesar, Pharm.D.

Director of Pharmacy
Albany Medical Center
Albany, NY

James Leggett Jr., M.D.

Associate Professor of Medicine
Oregon Health Sciences University
Portland, OR

Arthur Levin, M.P.H.

Consumer Representative
Director, Center for Medical Consumers
New York, NY

Lewis Nelson, M.D.

Director, Medical Toxicology Fellowship
Program
New York University School of Medicine
New York, NY

Edward Septimus, M.D.

Houston, TX

James Steckelberg, M.D.

Chairman, Division of Infectious Diseases
Mayo Clinic
Rochester, MN

Jeanine Thomas

Patient Representative
Methicillin Resistant Staphylococcus Aureus
(MRSA) Survivors Network
Willowbrook, IL

Melvin Weinstein, M.D.

Professor of Medicine and Pathology
Robert Wood Johnson Medical School
University of Medicine and Dentistry of New
Jersey
New Brunswick, NJ

Anti-Infective Drugs Advisory Committee Meeting

November 18, 2008

Non-Inferiority Margin Justification for complicated Skin and Skin Structure Infections (cSSSI)
Holiday Inn/College, Maryland

TEMPORARY MEMBERS (Non-Voting)

Henry Black, M.D.

Clinical Professor of Internal Medicine
New York University School of Medicine
New York, NY

Janet Cragan, M.D.

Medical Officer
National Center on Birth Defects and
Developmental Disabilities
Centers for Disease Control and Prevention
Atlanta, GA

Jeffery Kopp, M.D.

Staff Clinician
Kidney Disease Branch
NIDDK, National Institutes of Health
Bethesda, MD

Philip Mirkes, Ph.D.

Vancouver, WA

Emil Paganini, M.D.

Critical Care Nephrology Consulting
Chesterland, OH

Micheal Shelby, Ph.D.

National Institute of Environmental Health
Sciences
National Institutes of Medicine
Research Triangle, NC

Mary Alice Smith, Ph.D.

Professor
Environmental Health Science
University of Georgia
Atlanta, GA

FDA PARTICIPANTS (Non-Voting)

Edward Cox, M.D., M.P.H.

Director
Office of Antimicrobial Products

Katherine Laessig, M.D.

Deputy Director
Division of Anti-infective and Ophthalmology Products

Sumati Nambiar, M.D., M.P.H.

Deputy Director for Safety

Janice Pohlman, M.D., M.P.H.

Medical Officer
Division of Anti-infective and Ophthalmology Products

Thamban Valappil, Ph.D.

Mathematical Statistician
Office of Biostatistics